AstraZeneca is selling European rights (excluding Spain and the UK) to the erstwhile blockbuster cholesterol drug Crestor to German pharmaceutical company Grünenthal as the British drugmaker focuses on cancer treatments.
The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
One week after announcing positive data from ORION-10, the second of three 19-month Phase III trials for inclisiran for lowering cholesterol, The Medicines Co. was acquired by Novartis.
Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.
High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.
Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.
Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.
FDA snubs Novartis bid to repurpose inflammation drug for heart attacksBlood, Cholesterol Lowering, Clinical Trials, Complete Response Letter, FDA, FDA/Regulatory, Fever, Heart Attacks, Inflammation, Inflammatory Diseases, Mediterranean Fever, Mediterranean Fever, Non-Small Cell Lung Cancer (NSCLC), Pricing, Proteins, Rare Inflammatory Diseases, Scientists, Therapeutics
The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.
Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for AtherosclerosisAtherosclerosis, Biologics, Biopharmaceutical, Blood Vessels, Business, Cholesterol Lowering, Contract Development Manufacturing Organization (CDMO), Incubators, Innovation, Plaque, R&D, Statins, Vascular DIsease
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.